NCT06777979View on ClinicalTrials.gov

CD19-CD22-Bispecific Chimeric Antigen Receptor (CAR) T Cell Therapy for Pediatric Patients With Acute Lymphoblastic Leukemia

PHASE1RecruitingINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

April 28, 2025

Primary Completion Date

January 31, 2030

Study Completion Date

January 31, 2031

Conditions
Acute Lymphoblastic LeukemiaRecurrent Acute Lymphoblastic LeukemiaRecurrent B Acute Lymphoblastic Leukemia
Interventions
DRUG

Fludarabine

IV

DRUG

Cyclophosphamide

IV

DRUG

Mesna

IV

DEVICE

CD19-CD22 CAR T cell infusion

CAR T cell infusion will be given intravenously, either centrally or peripherally.

Trial Locations (1)

38105

RECRUITING

St. Jude Children's Research Hospital, Memphis

All Listed Sponsors
lead

St. Jude Children's Research Hospital

OTHER